BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 2016;103:125-38. [PMID: 26758972 DOI: 10.1159/000443170] [Cited by in Crossref: 205] [Cited by in F6Publishing: 170] [Article Influence: 41.0] [Reference Citation Analysis]
Number Citing Articles
1 Aalbersberg EA, Huizing DM, Walraven I, de Wit-van der Veen BJ, Kulkarni HR, Singh A, Stokkel MP, Baum RP. Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients. J Nucl Med 2019;60:1259-65. [DOI: 10.2967/jnumed.118.224386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
2 Fouché M, Bouffard Y, Le Goff MC, Prothet J, Malavieille F, Sagnard P, Christin F, Hayi-Slayman D, Pasquer A, Poncet G, Walter T, Rimmelé T. Intraoperative carcinoid syndrome during small-bowel neuroendocrine tumour surgery. Endocr Connect 2018;7:1245-50. [PMID: 30352418 DOI: 10.1530/EC-18-0324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
3 Dawod M, Gordoa TA, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel M, Lamarca A. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Curr Treat Options Oncol 2021;22:73. [PMID: 34185197 DOI: 10.1007/s11864-021-00863-y] [Reference Citation Analysis]
4 Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J, McNamara MG, Moghadam S, Rogan J, Mansoor W, Hubner RA, Clark C, Chakrabarty B, Valle JW. PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget 2018;9:14922-38. [PMID: 29599916 DOI: 10.18632/oncotarget.24464] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
5 Deroose CM, Hindié E, Kebebew E, Goichot B, Pacak K, Taïeb D, Imperiale A. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. J Nucl Med 2016;57:1949-56. [PMID: 27811124 DOI: 10.2967/jnumed.116.179234] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 15.0] [Reference Citation Analysis]
6 Mora-Guzmán I, Muñoz de Nova JL, Martín-Pérez E. Neuroendocrine tumours within a Meckel's diverticulum. Ann R Coll Surg Engl 2018;100:e10-1. [PMID: 29046099 DOI: 10.1308/rcsann.2017.0180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Ducreux M. Carcinoid syndrome in neuroendocrine tumors: a prognostic effect? The Lancet Oncology 2017;18:426-8. [DOI: 10.1016/s1470-2045(17)30159-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Daskalakis K, Norlén O, Karakatsanis A, Hellman P, Larsson R, Nygren P, Stålberg P. Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors. Endocr Relat Cancer 2018;25:471-80. [PMID: 29440231 DOI: 10.1530/ERC-17-0404] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Tirosh A, Papadakis GZ, Millo C, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, Shell J, Green P, Keutgen XM, Patel D, Nilubol N, Kebebew E. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements. Eur J Endocrinol 2017;176:575-82. [PMID: 28289088 DOI: 10.1530/EJE-16-1079] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
10 Rinzivillo M, Partelli S, Prosperi D, Capurso G, Pizzichini P, Iannicelli E, Merola E, Muffatti F, Scopinaro F, Schillaci O, Salgarello M, Falconi M, Delle Fave G, Panzuto F. Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms. Oncologist 2018;23:186-92. [PMID: 29118267 DOI: 10.1634/theoncologist.2017-0278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
11 Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, Weber MM, Ahmadzadehfar H, Schreckenberger M, Miederer M, Essler M. Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors. Clin Nucl Med 2019;44:e329-35. [DOI: 10.1097/rlu.0000000000002532] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 9.5] [Reference Citation Analysis]
12 Kudsi OY, Chang K, Bou-Ayash N. Robotic approach to delayed anastomotic leakage after ileocaecectomy for a neuroendocrine tumour - a video vignette. Colorectal Dis 2020;22:1470. [PMID: 32372480 DOI: 10.1111/codi.15108] [Reference Citation Analysis]
13 Kaçmaz E, Klümpen HJ, Bemelman WA, Nieveen van Dijkum EJM, Engelsman AF, Tanis PJ. Evaluating Nationwide Application of Minimally Invasive Surgery for Treatment of Small Bowel Neuroendocrine Neoplasms. World J Surg 2021;45:2463-70. [PMID: 33783584 DOI: 10.1007/s00268-021-06036-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lamarca A, Clouston H, Barriuso J, McNamara MG, Frizziero M, Mansoor W, Hubner RA, Manoharan P, O'Dwyer S, Valle JW. Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. J Clin Med 2019;8:E1630. [PMID: 31590343 DOI: 10.3390/jcm8101630] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Tsilimigras DI, Ntanasis-Stathopoulos I, Kostakis ID, Moris D, Schizas D, Cloyd JM, Pawlik TM. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis. J Gastrointest Surg. 2019;23:1044-1054. [PMID: 30671800 DOI: 10.1007/s11605-018-04094-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
16 Niederle B, Selberherr A, Niederle MB. How to Manage Small Intestine (Jejunal and Ileal) Neuroendocrine Neoplasms Presenting with Liver Metastases? Curr Oncol Rep 2021;23:85. [PMID: 34018081 DOI: 10.1007/s11912-021-01074-2] [Reference Citation Analysis]
17 Faron M, Laas E. [Does sentinel lymph node identification has indication in digestive cancers?]. Bull Cancer 2020;107:660-5. [PMID: 31627907 DOI: 10.1016/j.bulcan.2019.06.013] [Reference Citation Analysis]
18 de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, Do Cao C, Frampas E, Gaujoux S, Gincul R, Goudet P, Lombard-Bohas C, Poncet G, Smith D, Ruszniewski P, Lecomte T, Bouché O, Walter T, Cadiot G; Thésaurus National de Cancérologie Digestive (TNCD). Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis 2020;52:473-92. [PMID: 32234416 DOI: 10.1016/j.dld.2020.02.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 21.0] [Reference Citation Analysis]
19 Clement DS, Tesselaar ME, van Leerdam ME, Srirajaskanthan R, Ramage JK. Nutritional and vitamin status in patients with neuroendocrine neoplasms. World J Gastroenterol 2019; 25(10): 1171-1184 [PMID: 30886501 DOI: 10.3748/wjg.v25.i10.1171] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
20 Merola E, Rinzivillo M, Cicchese N, Capurso G, Panzuto F, Delle Fave G. Digestive neuroendocrine neoplasms: A 2016 overview. Dig Liver Dis. 2016;48:829-835. [PMID: 27212431 DOI: 10.1016/j.dld.2016.04.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021;146:56-73. [PMID: 33588146 DOI: 10.1016/j.ejca.2021.01.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
22 Chiramel J, Almond R, Slagter A, Khan A, Wang X, Lim KHJ, Frizziero M, Chakrabarty B, Minicozzi A, Lamarca A, Mansoor W, Hubner RA, Valle JW, McNamara MG. Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours. World J Clin Oncol 2020; 11(4): 205-216 [PMID: 32355642 DOI: 10.5306/wjco.v11.i4.205] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Brandi G, Paragona M, Campana D, Brighi N, Bondi A, Pantaleo MA, Corbelli J, Barbera MA, Biasco G. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms. Journal of Chemotherapy 2017;30:53-8. [DOI: 10.1080/1120009x.2017.1340127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Johnbeck CB, Knigge U, Langer SW, Loft A, Berthelsen AK, Federspiel B, Binderup T, Kjaer A. Prognostic Value of 18 F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18 F-FDG PET and Ki-67 in 100 Patients. J Nucl Med 2016;57:1851-7. [DOI: 10.2967/jnumed.116.174714] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
25 Appetecchia M, Lauretta R, Rota F, Carlini M. Neuroendocrine Tumors Biomarkers. In: Carlini M, editor. Abdominal Neuroendocrine Tumors. Milano: Springer Milan; 2018. pp. 65-78. [DOI: 10.1007/978-88-470-3955-1_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Dillon JS, Chandrasekharan C. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. Future Oncol 2018;14:1155-64. [PMID: 29350062 DOI: 10.2217/fon-2017-0340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
27 Kaçmaz E, Sarasqueta AF, van Eeden S, Dreijerink KMA, Klümpen HJ, Tanis PJ, van Dijkum EJMN, Engelsman AF. Update on Incidence, Prevalence, Treatment and Survival of Patients with Small Bowel Neuroendocrine Neoplasms in the Netherlands. World J Surg 2021;45:2482-91. [PMID: 33895862 DOI: 10.1007/s00268-021-06119-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lamberti G, Ceccarelli C, Brighi N, Maggio I, Santini D, Mosconi C, Ricci C, Biasco G, Campana D. Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors. Gastroenterol Res Pract 2017;2017:7872519. [PMID: 29213282 DOI: 10.1155/2017/7872519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
29 Herrera-martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocrine-Related Cancer 2019;26:R157-79. [DOI: 10.1530/erc-18-0354] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
30 Alexandraki KI, Daskalakis K, Tsoli M, Grossman AB, Kaltsas GA. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Trends in Endocrinology & Metabolism 2020;31:239-55. [DOI: 10.1016/j.tem.2019.11.003] [Reference Citation Analysis]
31 Shi M, Fan Z, Xu J, Yang J, Li Y, Gao C, Su P, Wang X, Zhan H. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs. Biochim Biophys Acta Rev Cancer 2021;1876:188637. [PMID: 34678439 DOI: 10.1016/j.bbcan.2021.188637] [Reference Citation Analysis]
32 Grant KM, Livie C, Smith K, Leung CH, Johnston S. A rapid liquid chromatography-tandem mass spectrometry method for the analysis of urinary 5-hydroxyindoleacetic acid (5-HIAA) that incorporates a 13C-labelled internal standard. Ann Clin Biochem 2021;:45632211038021. [PMID: 34325535 DOI: 10.1177/00045632211038021] [Reference Citation Analysis]
33 Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pellè E, Kolasińska-Ćwikła A, Zandee W, Laskaratos F, de Mestier L, Lamarca A, Hernando J, Cwikla J, Strosberg J, de Herder W, Caplin M, Cives M, van Leeuwaarde R. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%? Oncologist 2021;26:294-301. [PMID: 33301235 DOI: 10.1002/onco.13633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46:715-731. [PMID: 28609357 DOI: 10.1097/mpa.0000000000000846] [Cited by in Crossref: 127] [Cited by in F6Publishing: 57] [Article Influence: 42.3] [Reference Citation Analysis]
35 Massironi S, Del Gobbo A, Cavalcoli F, Fiori S, Conte D, Pellegrinelli A, Milione M, Ferrero S. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence. Endocrine 2017;58:360-7. [PMID: 28210937 DOI: 10.1007/s12020-017-1249-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
36 Berzaczy D, Giraudo C, Haug AR, Raderer M, Senn D, Karanikas G, Weber M, Mayerhoefer ME. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clin Nucl Med 2017;42:669-74. [PMID: 28682844 DOI: 10.1097/RLU.0000000000001753] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 10.3] [Reference Citation Analysis]
37 Reed NS. Neuroendocrine tumours of the gynecological tract. Current Opinion in Oncology 2016;28:412-8. [DOI: 10.1097/cco.0000000000000321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
38 Fottner C, Ferrata M, Weber MM. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose? Rev Endocr Metab Disord. 2017;18:393-410. [PMID: 29256148 DOI: 10.1007/s11154-017-9438-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
39 Citterio D, Pusceddu S, Facciorusso A, Coppa J, Milione M, Buzzoni R, Bongini M, deBraud F, Mazzaferro V. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. European Journal of Surgical Oncology (EJSO) 2017;43:380-7. [DOI: 10.1016/j.ejso.2016.10.031] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
40 Blažević A, Brabander T, Zandee WT, Hofland J, Franssen GJH, van Velthuysen MF, Feelders RA, De Herder WW. Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours. Cancers (Basel) 2021;13:443. [PMID: 33503893 DOI: 10.3390/cancers13030443] [Reference Citation Analysis]
41 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 18.5] [Reference Citation Analysis]
42 Ariotti R, Partelli S, Muffatti F, Andreasi V, Della Sala F, Falconi M. How should incidental NEN of the pancreas and gastrointestinal tract be followed? Rev Endocr Metab Disord 2018;19:139-44. [DOI: 10.1007/s11154-018-9445-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
43 Böning G, Kahn JF, Kaul D, Rotzinger R, Freyhardt P, Pavel M, Streitparth F. CT follow-up in patients with neuroendocrine tumors (NETs): combined radiation and contrast dose reduction. Acta Radiol 2018;59:517-26. [PMID: 28786299 DOI: 10.1177/0284185117726101] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
44 Pape UF, Maasberg S, Jann H, Pschowski R, Krüger S, Prasad V, Denecke T, Wiedenmann B, Pascher A. Management of follow-up of neuroendocrine neoplasias. Best Pract Res Clin Endocrinol Metab 2016;30:129-40. [PMID: 26971849 DOI: 10.1016/j.beem.2016.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
45 Herrera-Martínez AD, van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Culler MD, de Herder WW, Luque RM, Feelders RA, Hofland LJ. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. Endocr Relat Cancer 2019;26:585-99. [PMID: 30939452 DOI: 10.1530/ERC-19-0086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
46 Ye X, Wang L, Xing Y, Song C. Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases. BMC Gastroenterol 2020;20:342. [PMID: 33059631 DOI: 10.1186/s12876-020-01487-6] [Reference Citation Analysis]
47 Manguso N, Gangi A. ASO Author Reflections: Assessing the Value of Primary Tumor Resection in Midgut Neuroendocrine Tumors with Liver-Only Metastases. Ann Surg Oncol 2020;27:4533-4. [PMID: 32572852 DOI: 10.1245/s10434-020-08753-7] [Reference Citation Analysis]
48 Zandee WT, de Herder WW. The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. Neuroendocrinology 2018;106:357-65. [PMID: 29320780 DOI: 10.1159/000486096] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
49 Sagar VM, Shah T, Malhi H, Parkinson S, Shetty S, Cooper SC. Home parenteral nutrition in neuroendocrine tumour intestinal failure: improved quality of life and longevity. BMJ Support Palliat Care 2020:bmjspcare-2020-002562. [PMID: 32917652 DOI: 10.1136/bmjspcare-2020-002562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Larouche V, Akirov A, Alshehri S, Ezzat S. Management of Small Bowel Neuroendocrine Tumors. Cancers (Basel) 2019;11:E1395. [PMID: 31540509 DOI: 10.3390/cancers11091395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
51 Wedin M, Mehta S, Angerås-Kraftling J, Wallin G, Daskalakis K. The Role of Serum 5-HIAA as a Predictor of Progression and an Alternative to 24-h Urine 5-HIAA in Well-Differentiated Neuroendocrine Neoplasms. Biology (Basel) 2021;10:76. [PMID: 33494283 DOI: 10.3390/biology10020076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, Berzaczy D, Raderer M, Preusser M, Hochmair M, Kiesewetter B, Scheuba C, Ba-Ssalamah A, Karanikas G, Kesselbacher J, Prager G, Dieckmann K, Polterauer S, Weber M, Rausch I, Brauner B, Eidherr H, Wadsak W, Haug AR. PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging 2020;47:51-60. [PMID: 31410538 DOI: 10.1007/s00259-019-04452-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 16.5] [Reference Citation Analysis]
53 Gomes Marin JF, Nunes RF, Coutinho AM, Zaniboni EC, Costa LB, Barbosa FG, Queiroz MA, Cerri GG, Buchpiguel CA. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Radiographics 2020;40:1715-40. [PMID: 33001789 DOI: 10.1148/rg.2020200021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
54 Blažević A, Zandee WT, Franssen GJH, Hofland J, van Velthuysen MF, Hofland LJ, Feelders RA, de Herder WW. Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocr Relat Cancer 2018;25:245-54. [PMID: 29255095 DOI: 10.1530/ERC-17-0282] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
55 Dhanani J, Pattison DA, Burge M, Williams J, Riedel B, Hicks RJ, Reade MC. Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. J Crit Care 2020;60:319-22. [PMID: 32928590 DOI: 10.1016/j.jcrc.2020.08.011] [Reference Citation Analysis]
56 Lesén E, Granfeldt D, Houchard A, Berthon A, Dinet J, Gabriel S, Björstad Å, Björholt I, Elf AK, Johanson V. Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-A population-based register-linkage study. Eur J Cancer Care (Engl) 2019;28:e12983. [PMID: 30652364 DOI: 10.1111/ecc.12983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
57 Folkestad O, Wasmuth HH, Mjønes P, Fougner R, Hauso Ø, Fossmark R. Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours-A Single Centre Cohort. Cancers (Basel) 2021;13:3985. [PMID: 34439140 DOI: 10.3390/cancers13163985] [Reference Citation Analysis]
58 Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, Pavlakis N. Prognostic and predictive biomarkers in neuroendocrine tumours. Critical Reviews in Oncology/Hematology 2017;113:268-82. [DOI: 10.1016/j.critrevonc.2017.03.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
59 Kaçmaz E, van Eeden S, Koppes JCC, Klümpen HJ, Bemelman WA, Nieveen van Dijkum EJM, Engelsman AF, Tanis PJ. Value of Laparoscopy for Resection of Small Bowel Neuroendocrine Neoplasms Including Central Mesenteric Lymphadenectomy. Dis Colon Rectum 2021. [PMID: 33661232 DOI: 10.1097/DCR.0000000000001915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Bösch F, Bruewer K, D'Anastasi M, Ilhan H, Knoesel T, Pratschke S, Thomas M, Rentsch M, Guba M, Werner J, Angele MK. Neuroendocrine tumors of the small intestine causing a desmoplastic reaction of the mesentery are a more aggressive cohort. Surgery 2018;164:1093-9. [PMID: 30076029 DOI: 10.1016/j.surg.2018.06.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
61 Sagar VM, Cooper SC, Johnson J, Shetty S, Shah T. Gastrointestinal manifestations of neuroendocrine tumours: their investigation and management. Postgrad Med J. 2017;93:494-497. [PMID: 28600342 DOI: 10.1136/postgradmedj-2017-134847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Meoni G, Giommoni E, Petreni P, Pillozzi S, Mazzoni F, Pellegrini E, Brugia M, Lunghi A, Muto A, Antonuzzo L. Somatostatin analogs in pregnant patients with neuroendocrine tumor. Anti-Cancer Drugs 2020;31:1096-8. [DOI: 10.1097/cad.0000000000000967] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Kaçmaz E, Chen JW, Tanis PJ, Nieveen van Dijkum EJM, Engelsman AF. Postoperative morbidity and mortality after surgical resection of small bowel neuroendocrine neoplasms: A systematic review and meta-analysis. J Neuroendocrinol 2021;33:e13008. [PMID: 34235792 DOI: 10.1111/jne.13008] [Reference Citation Analysis]
64 Numbere N, Huber AR, Shi C, Cates JMM, Gonzalez RS. Should Ki67 immunohistochemistry be performed on all lesions in multifocal small intestinal neuroendocrine tumours? Histopathology 2019;74:424-9. [PMID: 30326145 DOI: 10.1111/his.13771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
65 Folkestad O, Wasmuth HH, Mjønes P, Fougner R, Hauso Ø, Fossmark R. Survival and disease recurrence in patients operated for small intestinal neuroendocrine tumors at a referral hospital. Surg Oncol 2020;35:336-43. [PMID: 32979699 DOI: 10.1016/j.suronc.2020.09.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Ouvrard E, Chevalier E, Addeo P, Sahakian N, Detour J, Goichot B, Bachellier P, Karcher G, Taïeb D, Imperiale A. Intraindividual comparison of 18 F-FDOPA and 68 Ga-DOTATOC PET/CT detection rate for metastatic assessment in patients with ileal neuroendocrine tumours. Clin Endocrinol (Oxf) 2021;94:66-73. [PMID: 32790887 DOI: 10.1111/cen.14312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
67 de Mestier L, Savagner F, Brixi H, Do Cao C, Dominguez-Tinajero S, Roquin G, Goichot B, Hentic O, Dubreuil O, Hautefeuille V, Walter T, Cadiot G. Plasmatic and Urinary 5-Hydroxyindolacetic Acid Measurements in Patients With Midgut Neuroendocrine Tumors: A GTE Study. J Clin Endocrinol Metab 2021;106:e1673-82. [PMID: 33382891 DOI: 10.1210/clinem/dgaa924] [Reference Citation Analysis]
68 Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L, Franca Bezerra RO, Borg P, Vietti Violi N, Vidal Trueba H, de Mestier L, Schaefer N, Sundin A, Costa F, Pavel M, Dromain C; Knowledge Network. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study. Oncologist 2019;24:e1082-90. [PMID: 30910869 DOI: 10.1634/theoncologist.2018-0672] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
69 Christiansen LB, Cremer SE, Helander A, Madsen T, Reimann MJ, Møller JE, Höglund K, Ljungvall I, Häggström J, Olsen LH. Urine 5-hydroxyindoleacetic acid in Cavalier King Charles spaniels with preclinical myxomatous mitral valve disease. Vet J 2019;250:36-43. [PMID: 31383418 DOI: 10.1016/j.tvjl.2019.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Darbà J, Marsà A. Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources. BMC Cancer 2019;19:1226. [PMID: 31842791 DOI: 10.1186/s12885-019-6412-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
71 van Faassen M, Bouma G, de Hosson LD, Peters MAM, Kats-Ugurlu G, de Vries EGE, Walenkamp AME, Kema IP. Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors. Clin Chem 2019;65:1388-96. [PMID: 31551315 DOI: 10.1373/clinchem.2019.305359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
72 Pedraza-Arévalo S, Gahete MD, Alors-Pérez E, Luque RM, Castaño JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord 2018;19:179-92. [PMID: 30293213 DOI: 10.1007/s11154-018-9465-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
73 Basendowah MH, Ashour MA, Hassan AY, Alshaynawi S, Alyazidi LK. Multiple Small Intestinal Neuroendocrine Tumors With Findings of Intestinal Obstruction. Cureus 2021;13:e17629. [PMID: 34646678 DOI: 10.7759/cureus.17629] [Reference Citation Analysis]
74 Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors. J Surg Oncol 2019;120:1311-7. [DOI: 10.1002/jso.25727] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
75 Gamboa AC, Liu Y, Lee RM, Zaidi MY, Staley CA, Russell MC, Cardona K, Sullivan PS, Maithel SK. A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique. J Surg Oncol 2019;120:932-9. [PMID: 31448820 DOI: 10.1002/jso.25679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
76 Alexandraki K, Angelousi A, Boutzios G, Kyriakopoulos G, Rontogianni D, Kaltsas G. Management of neuroendocrine tumors of unknown primary. Rev Endocr Metab Disord 2017;18:423-31. [PMID: 29199361 DOI: 10.1007/s11154-017-9437-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
77 Zheng M, Li Y, Li T, Zhang L, Zhou L. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis. Cancer Med 2019;8:5128-36. [PMID: 31328428 DOI: 10.1002/cam4.2431] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
78 Dior M, Dreanic J, Prieux-Klotz C, Brieau B, Brezault C, Coriat R. [Mid gut neuroendocrine tumors: News on medical treatment]. Presse Med 2017;46:4-10. [PMID: 28089247 DOI: 10.1016/j.lpm.2016.09.001] [Reference Citation Analysis]
79 Pirasteh A, Riedl C, Mayerhoefer ME, Giancipoli RG, Larson SM, Bodei L. PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype? Clin Transl Imaging 2019;7:405-13. [PMID: 33282794 DOI: 10.1007/s40336-019-00344-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
80 Patanè E, Sgardello SD, Guendil B, Fournier I, Abbassi Z. Unexpected Finding of a Small Intestinal Neuroendocrine Tumor: A Case Report and Literature Review. Am J Case Rep 2020;21:e917759. [PMID: 31988272 DOI: 10.12659/AJCR.917759] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Bauci G, Kolb W, Janczak J. Is the Meckel diverticulum still a bad boy in general surgery? Case report of an intestinal obstruction managed through a single-port access and review of the literature. J Surg Case Rep 2021;2021:rjaa584. [PMID: 33532050 DOI: 10.1093/jscr/rjaa584] [Reference Citation Analysis]
82 Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Manag Res 2019;11:7537-56. [PMID: 31496810 DOI: 10.2147/CMAR.S181439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
83 Pathirannehalage Don C, Sforza D, Siragusa L, Sensi B, Ciancio Manuelli M, Telesca R, Savino L, Ferrazzoli V, Grande S, Villa M, Grande M. Ileal Neuroendocrine Tumor in a Patient with Sclerosing Mesenteritis: Which Came First? Am J Case Rep 2021;22:e931372. [PMID: 34092781 DOI: 10.12659/AJCR.931372] [Reference Citation Analysis]
84 Selberherr A, Niederle MB, Niederle B. Surgical Treatment of Small Intestinal Neuroendocrine Tumors G1/G2. Visc Med 2017;33:340-3. [PMID: 29177162 DOI: 10.1159/000477786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
85 Artale S, Barzaghi S, Grillo N, Maggi C, Lepori S, Butti C, Bovio A, Barbarini L, Colombo A, Zanlorenzi L, Castiglioni E, Trojani A. Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors. Nutr Cancer 2020;:1-10. [PMID: 33148022 DOI: 10.1080/01635581.2020.1838572] [Reference Citation Analysis]
86 Tran CG, Sherman SK, Howe JR. The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:2741-51. [PMID: 33452604 DOI: 10.1245/s10434-020-09566-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Granata V, Fusco R, Setola SV, Castelguidone ELD, Camera L, Tafuto S, Avallone A, Belli A, Incollingo P, Palaia R, Izzo F, Petrillo A. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge. Radiol Oncol. 2019;53:373-387. [PMID: 31652122 DOI: 10.2478/raon-2019-0040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
88 Bertani E, Collamati F, Colandrea M, Faccini R, Fazio N, Ferrari ME, Fischetti M, Fumagalli Romario U, Funicelli L, De Simoni M, Mancini-Terracciano C, Mirabelli R, Morganti S, Papi S, Pisa E, Solfaroli-Camillocci E, Spada F, Cremonesi M, Grana CM. First Ex Vivo Results of β--Radioguided Surgery in Small Intestine Neuroendocrine Tumors with 90Y-DOTATOC. Cancer Biother Radiopharm 2021;36:397-406. [PMID: 33601932 DOI: 10.1089/cbr.2020.4487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
89 Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocrine-Related Cancer 2018;25:R11-29. [DOI: 10.1530/erc-17-0269] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 16.3] [Reference Citation Analysis]
90 Cavalcoli F, Garrahy A, Castellaneta M, Tamagno G. Epidemiology of Neuroendocrine Tumours: By Site of Tumour and by Geographical Area. In: Colao A, Faggiano A, de Herder W, editors. Neuroendocrine Tumors in Real Life. Cham: Springer International Publishing; 2018. pp. 3-27. [DOI: 10.1007/978-3-319-59024-0_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Ronde EM, Heidsma CM, Eskes AM, Schopman JE, Nieveen van Dijkum EJM. Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Eur J Cancer Care (Engl) 2021;30:e13504. [PMID: 34462979 DOI: 10.1111/ecc.13504] [Reference Citation Analysis]
92 Kiesewetter B, Duan H, Lamm W, Haug A, Riss P, Selberherr A, Scheuba C, Raderer M. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs. Oncologist. 2019;24:255-258. [PMID: 30171068 DOI: 10.1634/theoncologist.2018-0191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
93 Pavel M, Becerra C, Grosch K, Cheung W, Hasskarl J, Yao J. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial. Clin Pharmacol Ther 2017;101:462-8. [DOI: 10.1002/cpt.559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
94 Xie JB, Pang YS, Li X, Wu XT. Role of Removed Lymph Nodes on the Prognosis of M0 Small-Bowel Neuroendocrine Tumors: a Propensity Score Matching Analysis from SEER Database. J Gastrointest Surg 2021. [PMID: 34109533 DOI: 10.1007/s11605-021-04994-3] [Reference Citation Analysis]
95 Picchia S, Terlizzo M, Bali MA. Radiological and histological findings of an asymptomatic ever-increasing neoplasm: The small bowel neuroendocrine tumor (NET). Curr Probl Cancer 2020;44:100495. [PMID: 31376987 DOI: 10.1016/j.currproblcancer.2019.07.001] [Reference Citation Analysis]
96 Elf AK, Johanson V, Marin I, Bergström A, Nilsson O, Svensson J, Wängberg B, Bernhardt P, Elias E. Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers (Basel) 2021;13:2035. [PMID: 33922482 DOI: 10.3390/cancers13092035] [Reference Citation Analysis]
97 Sitani K, Parghane RV, Talole S, Basu S. Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. Br J Radiol 2021;94:20201041. [PMID: 33095671 DOI: 10.1259/bjr.20201041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
98 Tsilimigras DI, Hyer JM, Paredes AZ, Ejaz A, Cloyd JM, Beane JD, Dillhoff M, Tsung A, Pawlik TM. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.J Gastrointest Surg. 2021;. [PMID: 33403563 DOI: 10.1007/s11605-020-04898-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Selberherr A, Freermann S, Koperek O, Niederle MB, Riss P, Scheuba C, Niederle B. Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival? Orphanet J Rare Dis 2021;16:30. [PMID: 33446229 DOI: 10.1186/s13023-021-01677-9] [Reference Citation Analysis]
100 Malczewska A, Witkowska M, Makulik K, Bocian A, Walter A, Pilch-Kowalczyk J, Zajęcki W, Bodei L, Oberg KE, Kos-Kudła B. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocr Connect 2019:EC-19-0030. [PMID: 30865931 DOI: 10.1530/EC-19-0030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
101 Alexandraki KI, Daskalakis K, Tsoli M, Grossman AB, Kaltsas GA. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Trends Endocrinol Metab 2020;31:239-55. [PMID: 31839442 DOI: 10.1016/j.tem.2019.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
102 Kiesewetter B, Raderer M. How I treat neuroendocrine tumours. ESMO Open 2020;5:e000811. [PMID: 32817134 DOI: 10.1136/esmoopen-2020-000811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
103 Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103:153-171. [PMID: 26742109 DOI: 10.1159/000443171] [Cited by in Crossref: 531] [Cited by in F6Publishing: 458] [Article Influence: 106.2] [Reference Citation Analysis]
104 Petersenn S, Koch CA. Neuroendocrine neoplasms – still a challenge despite major advances in clinical care with the development of specialized guidelines. Rev Endocr Metab Disord 2017;18:373-8. [DOI: 10.1007/s11154-018-9442-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
105 Ewang-emukowhate M, Nair D, Caplin M. The role of 5-hydroxyindoleacetic acid in neuroendocrine tumors: the journey so far. International Journal of Endocrine Oncology 2019;6:IJE17. [DOI: 10.2217/ije-2019-0001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Papantoniou D, Grönberg M, Landerholm K, Welin S, Ziolkowska B, Nordvall D, Janson ET. Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2. Endocrine 2021;72:893-904. [PMID: 33244704 DOI: 10.1007/s12020-020-02534-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
107 Weber F, Dralle H. Chirurgische Aspekte bei kleinen neuroendokrinen Dünndarmtumoren. Chirurg 2018;89:428-33. [DOI: 10.1007/s00104-018-0607-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
108 Pedrazzani C, Conti C, Valdegamberi A, Davì MV, Cingarlini S, Scarpa A, Guglielmi A. Is Laparoscopic CME Right Hemicolectomy an Optimal Indication for NET of the Right Colon and Terminal Ileum? J Gastrointest Surg 2021;25:333-6. [DOI: 10.1007/s11605-020-04682-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
109 Davi MV, Pia A, Guarnotta V, Pizza G, Colao A, Faggiano A; NIKE Group. The treatment of hyperinsulinemic hypoglycaemia in adults: an update. J Endocrinol Invest 2017;40:9-20. [PMID: 27624297 DOI: 10.1007/s40618-016-0536-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
110 Carideo L, Prosperi D, Panzuto F, Magi L, Pratesi MS, Rinzivillo M, Annibale B, Signore A. Role of Combined [68Ga] Ga-DOTA-SST Analogues and [18F] FDG PET/CT in the Management of GEP-NENs: A Systematic Review. J Clin Med. 2019;8. [PMID: 31337043 DOI: 10.3390/jcm8071032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
111 Tirosh A, Kebebew E. The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Future Oncol 2018;14:111-22. [PMID: 29072093 DOI: 10.2217/fon-2017-0393] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
112 Ricci C, Campana D, Casadei C, Ingaldi C, Ambrosini V, Pagano N, Santini D, Mosconi C, Brighi N, Alberici L, Minni F, Casadei R. A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience. Endocrine 2019;64:702-7. [PMID: 30796689 DOI: 10.1007/s12020-019-01870-8] [Reference Citation Analysis]
113 Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018;4:1597-1604. [PMID: 30054622 DOI: 10.1001/jamaoncol.2018.2428] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
114 Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
115 Laskaratos FM, Diamantopoulos L, Walker M, Walton H, Khalifa M, El-Khouly F, Koffas A, Demetriou G, Caplin M, Toumpanakis C, Mandair D. Prognostic Factors for Survival among Patients with Small Bowel Neuroendocrine Tumours Associated with Mesenteric Desmoplasia. Neuroendocrinology 2018;106:366-80. [PMID: 29320779 DOI: 10.1159/000486097] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
116 Frilling A, Clift AK, Frampton AE, Bomanji J, Kaemmerer D, Al-Nahhas A, Alsafi A, Kidd M, Modlin IM, Hoersch D, Baum RP. A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms. Int J Med Sci 2021;18:2166-75. [PMID: 33859524 DOI: 10.7150/ijms.51740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Koffas A, Toumpanakis C. Managing carcinoid heart disease in patients with neuroendocrine tumors. Ann Endocrinol (Paris) 2021;82:187-92. [PMID: 33321109 DOI: 10.1016/j.ando.2020.12.007] [Reference Citation Analysis]
118 Gamboa AC, Liu Y, Lee RM, Zaidi MY, Staley CA, Kooby DA, Winer JH, Shah MM, Russell MC, Cardona K, Maithel SK. Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel? J Surg Oncol 2019;120:1293-301. [PMID: 31621090 DOI: 10.1002/jso.25731] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
119 Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors. J Surg Oncol 2020;122:204-11. [PMID: 32291778 DOI: 10.1002/jso.25930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
120 Deguelte S, Perrier M, Hammoutene C, Cadiot G, Kianmanesh R. Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors. J Clin Med. 2020;9. [PMID: 32708330 DOI: 10.3390/jcm9072319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
121 Mahuron KM, Kasai Y, Javeed ZA, Bergsland EK, Hirose K, Corvera CU, Nakakura EK. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. J Gastrointest Surg 2021. [PMID: 33742361 DOI: 10.1007/s11605-021-04974-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Lamberti G, Faggiano A, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, Pusceddu S, Albertelli M, Massironi S, Panzuto F, Badalamenti G, Riccardi F, Butturini G, Gelsomino F, De Divitiis C, Modica R, Bongiovanni A, La Salvia A, Torchio M, Colao A, Ferone D, Campana D. Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. J Clin Endocrinol Metab 2020;105:dgz035. [PMID: 31545377 DOI: 10.1210/clinem/dgz035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
123 Zhou B, Zhan C, Ding Y, Yan S, Zheng S. Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. Onco Targets Ther 2018;11:975-82. [PMID: 29503572 DOI: 10.2147/OTT.S158171] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
124 Almond L, Hodson J, Ford S, Gourevitch D, Roberts K, Shah T, Isaac J, Desai A. Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis. European Journal of Surgical Oncology (EJSO) 2017;43:1808-15. [DOI: 10.1016/j.ejso.2017.05.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
125 Fossmark R, Balto TM, Martinsen TC, Grønbech JE, Munkvold B, Mjønes PG, Waldum HL. Hepatic micrometastases outside macrometastases are present in all patients with ileal neuroendocrine primary tumour at the time of liver resection. Scand J Gastroenterol 2019;54:1003-7. [PMID: 31368380 DOI: 10.1080/00365521.2019.1647281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
126 Półtorak-Szymczak G, Budlewski T, Furmanek MI, Wierzba W, Sklinda K, Walecki J, Mruk B. Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The Review of Current Literature Emphasizing the Diagnostic Value of Chosen Imaging Methods. Front Oncol 2021;11:670233. [PMID: 34211845 DOI: 10.3389/fonc.2021.670233] [Reference Citation Analysis]
127 Lewis A, Raoof M, Ituarte PHG, Williams J, Melstrom L, Li D, Lee B, Singh G. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment. Ann Surg 2019;270:1131-7. [PMID: 29746336 DOI: 10.1097/SLA.0000000000002809] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 21.0] [Reference Citation Analysis]
128 Fehrenbach U, Kahn J, Fahlenkamp U, Baur A, Pavel M, Geisel D, Denecke T. Optimized imaging of the lower abdomen and pelvic region in hepatocyte-specific MRI: evaluation of a whole-abdomen first-pass shuttle protocol in patients with neuroendocrine neoplasms. Acta Radiol 2019;60:1074-83. [DOI: 10.1177/0284185118817936] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
129 Pobłocki J, Jasińska A, Syrenicz A, Andrysiak-Mamos E, Szczuko M. The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition. Nutrients 2020;12:E1437. [PMID: 32429294 DOI: 10.3390/nu12051437] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
130 Tirosh A, Nilubol N, Patel D, Kebebew E. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors. Endocr Pract 2018;24:710-7. [PMID: 30084688 DOI: 10.4158/EP-2018-0022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
131 Koffas A, Toumpanakis C. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opin Drug Saf 2021;20:321-34. [PMID: 33338383 DOI: 10.1080/14740338.2021.1867097] [Reference Citation Analysis]
132 Pirasteh A, Lovrec P, Bodei L. Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities. Rev Endocr Metab Disord 2021;22:539-52. [PMID: 33783695 DOI: 10.1007/s11154-021-09631-7] [Reference Citation Analysis]
133 Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 2016;5:174-87. [PMID: 27582247 DOI: 10.1530/EC-16-0043] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 9.8] [Reference Citation Analysis]
134 Kaçmaz E, Slooter MD, Nieveen van Dijkum EJM, Tanis PJ, Engelsman AF. Laparoscopic assisted central mesenteric lymph node dissection with bowel sparing resection of small bowel neuroendocrine tumours using fluorescence angiography – a video vignette. Colorectal Dis 2019;21:724-5. [DOI: 10.1111/codi.14616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
135 Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A. Head-to-Head Comparison of 64 Cu-DOTATATE and 68 Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. J Nucl Med 2017;58:451-7. [DOI: 10.2967/jnumed.116.180430] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 11.8] [Reference Citation Analysis]
136 Kaçmaz E, Slooter MD, Nieveen van Dijkum EJM, Tanis PJ, Engelsman AF. Fluorescence angiography guided resection of small bowel neuroendocrine neoplasms with mesenteric lymph node metastases. Eur J Surg Oncol 2021;47:1611-5. [PMID: 33353827 DOI: 10.1016/j.ejso.2020.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Kang A, Adamic B, Cooper CA, Paner GP, Werntz RP. Transurethral resection and surveillance of a well-differentiated neuroendocrine tumor in a ileal neobladder. Urol Case Rep 2020;32:101255. [PMID: 32477878 DOI: 10.1016/j.eucr.2020.101255] [Reference Citation Analysis]
138 Arvidsson Y, Rehammar A, Bergström A, Andersson E, Altiparmak G, Swärd C, Wängberg B, Kristiansson E, Nilsson O. miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival. Mod Pathol 2018;31:1302-17. [PMID: 29487354 DOI: 10.1038/s41379-018-0010-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
139 Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, Ilhan H, Knösel T, Mayerle J, Reincke M, Bartenstein P. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol 2018;6:404-15. [PMID: 29229497 DOI: 10.1016/S2213-8587(17)30401-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
140 Clement D, Ramage J, Srirajaskanthan R. Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. J Oncol 2020;2020:8341426. [PMID: 32322270 DOI: 10.1155/2020/8341426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
141 Pasquer A, Walter T, Rousset P, Hervieu V, Forestier J, Lombard-bohas C, Poncet G. Lymphadenectomy during Small Bowel Neuroendocrine Tumor Surgery: The Concept of Skip Metastases. Ann Surg Oncol 2016;23:804-8. [DOI: 10.1245/s10434-016-5574-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
142 Lim JY, Pommier RF. Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:622693. [PMID: 33732215 DOI: 10.3389/fendo.2021.622693] [Reference Citation Analysis]
143 Blažević A, Hofland J, Hofland LJ, Feelders RA, de Herder WW. Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. Endocr Relat Cancer 2018;25:R115-30. [PMID: 29233841 DOI: 10.1530/ERC-17-0380] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
144 Ingaldi C, Alberici L, Ricci C, Campana D, Mosconi C, Ambrosini V, Lamberti G, Manuzzi L, Minni F, Casadei R. Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis. Updates Surg 2021. [PMID: 34224086 DOI: 10.1007/s13304-021-01123-2] [Reference Citation Analysis]
145 Tsoli M, Alexandraki K, Xanthopoulos C, Kassi E, Kaltsas G. Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms. Horm Metab Res. 2020;52:614-620. [PMID: 32108932 DOI: 10.1055/a-1110-7251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
146 Rehfeld JF, Broedbaek K, Goetze JP, Knigge U, Hilsted LM. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours. Scandinavian Journal of Gastroenterology 2020;55:565-73. [DOI: 10.1080/00365521.2020.1759141] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
147 Merola E, Pavel ME, Panzuto F, Capurso G, Cicchese N, Rinke A, Gress TM, Iannicelli E, Prosperi D, Pizzichini P, Prasad V, Kump P, Lipp R, Partelli S, Falconi M, Wiedenmann B, Delle Fave G. Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. The Journal of Clinical Endocrinology & Metabolism 2017;102:1486-94. [DOI: 10.1210/jc.2016-3732] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
148 Chi W, Warner RRP, Chan DL, Singh S, Segelov E, Strosberg J, Wisnivesky J, Kim MK. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. Pancreas 2018;47:321-5. [PMID: 29401168 DOI: 10.1097/MPA.0000000000001005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
149 Albers MB, Almquist M, Bergenfelz A, Nordenström E. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias. Langenbecks Arch Surg 2020;405:137-43. [PMID: 32291468 DOI: 10.1007/s00423-020-01869-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
150 Mazziotti G, Mosca A, Frara S, Vitale G, Giustina A. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opin Pharmacother. 2017;18:1679-1689. [PMID: 29067877 DOI: 10.1080/14656566.2017.1391217] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
151 Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, Appetecchia M. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers (Basel) 2019;11:E1113. [PMID: 31382663 DOI: 10.3390/cancers11081113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
152 Giovannini E, Giovacchini G, Borsò E, Lazzeri P, Riondato M, Leoncini R, Duce V, Ciarmiello A. [ 68 Ga]-Dota Peptide PET/CT in Neuroendocrine Tumors: Main Clinical Applications. CRP 2019;12:11-22. [DOI: 10.2174/1874471012666181212101244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
153 Baekdal J, Krogh J, Klose M, Holmager P, Langer SW, Oturai P, Kjaer A, Federspiel B, Hilsted L, Rehfeld JF, Knigge U, Andreassen M. Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors. Diagnostics (Basel) 2020;10:E881. [PMID: 33138020 DOI: 10.3390/diagnostics10110881] [Reference Citation Analysis]
154 Gaertner F, Plum T, Kreppel B, Eppard E, Meisenheimer M, Strunk H, Bundschuh R, Sinnes J, Rösch F, Essler M. Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours. Nuclear Medicine and Biology 2019;76-77:1-9. [DOI: 10.1016/j.nucmedbio.2019.08.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
155 Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17:2191-2205. [PMID: 27635672 DOI: 10.1080/14656566.2016.1236916] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 6.2] [Reference Citation Analysis]
156 Castillo JG, Naib T, Zacks JS, Adams DH. Echocardiography in functional midgut neuroendocrine tumors: When and how often. Rev Endocr Metab Disord 2017;18:411-21. [DOI: 10.1007/s11154-017-9434-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
157 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021; 13(3): 231-255 [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Weber F, Dralle H. Value of ileus-prophylactic surgery for metastatic neuroendocrine midgut tumours. Best Pract Res Clin Endocrinol Metab 2019;33:101342. [PMID: 31628078 DOI: 10.1016/j.beem.2019.101342] [Reference Citation Analysis]
159 Koumarianou A, Alexandraki KI, Wallin G, Kaltsas G, Daskalakis K. Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review. J Clin Med. 2020;9. [PMID: 32521677 DOI: 10.3390/jcm9061777] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
160 van der Zwan JM, Siesling S, van Velthuysen L, Links T, Walenkamp A, Tesselaar M. Extra-Pulmonary Neuroendocrine Carcinomas: A Population-Based Study in the Netherlands. Neuroendocrinology 2018;107:50-9. [PMID: 29945149 DOI: 10.1159/000488987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
161 Daskalakis K, Tsolakis AV. Upfront surgery of small intestinal neuroendocrine tumors. Time to reconsider? World J Gastroenterol 2018; 24(29): 3201-3203 [PMID: 30090001 DOI: 10.3748/wjg.v24.i29.3201] [Reference Citation Analysis]
162 Salih Z, Lamarca A, Nonaka D, Hubner RA, de Liguori-Carino N, McNamara MG, Fulford P, Minicozzi A, O'Dwyer S, Chakrabarty B, Valle JW. The dark side of T1 non-appendiceal small bowel neuroendocrine tumors. Hum Pathol 2017;66:239-40. [PMID: 28499547 DOI: 10.1016/j.humpath.2017.02.030] [Reference Citation Analysis]
163 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
164 Mehta A, Kumar D, Chadha P, Goswami M, Vishwakarma G, Panigrahi M, Suryavanshi M, Panaych A. Diagnostic ability of real-time quantitative polymerase chain reaction versus immunohistochemistry for Ki-67 assessment in breast cancer: An Indian perspective. Indian J Med Res 2019;150:254-60. [PMID: 31719296 DOI: 10.4103/ijmr.IJMR_644_18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Mora-guzmán I, Muñoz de Nova JL, Martín-pérez E. Meckel's diverticulum in the adult: surgical treatment. Acta Chirurgica Belgica 2019;119:277-81. [DOI: 10.1080/00015458.2018.1503391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
166 Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist 2019;24:463-74. [PMID: 30355775 DOI: 10.1634/theoncologist.2018-0217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Hruban RH, Gaida MM, Thompson E, Hong SM, Noë M, Brosens LA, Jongepier M, Offerhaus GJA, Wood LD. Why is pancreatic cancer so deadly? The pathologist's view. J Pathol 2019;248:131-41. [PMID: 30838636 DOI: 10.1002/path.5260] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
168 Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019;10:2042018818804698. [PMID: 30800264 DOI: 10.1177/2042018818804698] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
169 Daskalakis K, Karakatsanis A, Stålberg P, Norlén O, Hellman P. Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg 2017;104:69-75. [PMID: 27861745 DOI: 10.1002/bjs.10333] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
170 Malik P, Pinto C, Naparst MS, Ward SC, Aronson A, Aalberg JJ, Divino CM, Kim MK. Impact of Mesenteric Mass in Patients With Midgut Neuroendocrine Tumors. Pancreas 2019;48:682-5. [PMID: 31091215 DOI: 10.1097/MPA.0000000000001309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
171 Rezende DT, Kawaguti FS, Safatle-Ribeiro AV, Tolentino LHL, Ribeiro Junior U, Maluf-Filho F. Underwater endoscopic resection of an ileal neuroendocrine tumor. Endoscopy 2021;53:E48-9. [PMID: 32503073 DOI: 10.1055/a-1178-0143] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, Tiensuu Janson E, Öberg K, Hellman P, Norlén O, Stålberg P. Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival. JAMA Oncol 2018;4:183-9. [PMID: 29049611 DOI: 10.1001/jamaoncol.2017.3326] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 18.5] [Reference Citation Analysis]
173 Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 2020;27:3270-80. [PMID: 32632880 DOI: 10.1245/s10434-020-08787-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
174 Lamarca A, Barriuso J, McNamara MG, Hubner RA, Valle JW. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opin Pharmacother. 2016;17:2487-2498. [PMID: 27817224 DOI: 10.1080/14656566.2016.1254191] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]